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Abstract
A major challenge in systems biology is integration of molecular findings for individual enzyme activities into a cohesive
high-level understanding of cellular metabolism and physiology/pathophysiology. However, meaningful prediction for how
a perturbed enzyme activity will globally impact metabolism in a cell, tissue or intact organisms is precluded by multiple
unknowns, including in vivo enzymatic rates, subcellular distribution and pathway interactions. To address this challenge,
metabolomics offers the potential to simultaneously survey changes in thousands of structurally diverse metabolites within
complex biological matrices. The present study assessed the capability of untargeted plasma metabolite profiling to
discover systemic changes arising from inactivation of xanthine oxidoreductase (XOR), an enzyme that catalyzes the final
steps in purine degradation. Using LC-MS coupled with a multivariate statistical data analysis platform, we confidently
surveyed .3,700 plasma metabolites (50–1,000 Da) for differential expression in XOR wildtype vs. mice with inactivated
XOR, arising from gene deletion or pharmacological inhibition. Results confirmed the predicted derangements in purine
metabolism, but also revealed unanticipated perturbations in metabolism of pyrimidines, nicotinamides, tryptophan,
phospholipids, Krebs and urea cycles, and revealed kidney dysfunction biomarkers. Histochemical studies confirmed and
characterized kidney failure in xor-nullizygous mice. These findings provide new insight into XOR functions and
demonstrate the power of untargeted metabolite profiling for systemic discovery of direct and indirect consequences of
gene mutations and drug treatments.
Citation: Chen Q, Park H-C, Goligorsky MS, Chander P, Fischer SM, et al. (2012) Untargeted Plasma Metabolite Profiling Reveals the Broad Systemic Consequences
of Xanthine Oxidoreductase Inactivation in Mice. PLoS ONE 7(6): e37149. doi:10.1371/journal.pone.0037149
Editor: Paul Cobine, Auburn University, United States of America
Received February 9, 2012; Accepted April 13, 2012; Published June 18, 2012
Copyright:  2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were supported by NIH (National Institute of Health) grants HL87062 (SSG), HD067244 (SSG), K45462 (MSG) and tDK84394 (MSG). The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: author Steven M. Fischer is employed by a commercial
company Agilent Technologies. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: ssgross@med.cornell.edu
Introduction
Metabolomics, the systems biology of small molecules, has
emerged in the post-genomic era as a powerful tool for profiling
differences in the expression of structurally diverse molecules in
complex biological mixtures [1–6]. In comparison to other ‘‘omics:
technologies, metabolomics offers the most proximal approach for
defining key differences between cell phenotypes. A significant
challenge to metabolomics is the untargeted discovery of changes
in metabolite expression that are hidden in large data matrices,
acquired using high-throughput analytical procedures. Notwith-
standing, untargeted profiling offers the potential to discover
disease-associated and drug-induced changes in the expression of
diverse small molecules in a biological fluid or tissue, revealing
biomarkers that can be used to inform on disease progression or
the efficacy of clinical treatments. In this regard, metabolomics can
serve as an extension of traditional (targeted) clinical analyses,
providing a far more comprehensive snapshot of the functional
status of a complex biological system [7]. The resulting
identification and quantification of disease and treatment-associ-
ated metabolites can trigger unanticipated hypotheses and novel
mechanistic insights.
The ideal metabolomic platform would be able to accurately
quantify the broad structural spectrum of small molecules that
reside in cells, tissues and biofluids, at their biological levels – an
elusive challenge. Notably, the extreme complexity of most
biological sample matrices demands multiple metabolite separa-
tion modes for broad analytical detection and molecular identi-
fication to be effectively approached. To meet this challenge,
recent developments in high-performance liquid chromatography
(LC) separations have provided promising platforms for the rapid
resolution of thousands of metabolites in biological extracts [8–13].
Combined with advances in MS instrumentation that enable rapid
acquisition of high-resolution accurate mass spectra and chemo-
metric platforms for automated data analysis and interpretation,
effective metabolomic strategies for profiling and identifying
diverse metabolites have emerged [14–17].
Xanthine oxidoreductase (XOR) is a molybdopterin-contain-
ing enzyme that catalyzes the two terminal steps in purine
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finally to uric acid. XOR exists in two interconvertible forms that
each yield ureate: xanthine oxidase (XO) and xanthine dehy-
drogenase. The distinction is that XO uses molecular oxygen as
its electron donor and generates superoxide as a product,
whereas xanthine dehydrogenase preferentially reduces NAD+
without superoxide generation. Xanthine dehydrogenase is
considered to be the predominant physiological form of XOR
in cells. Over the past two decades, there has been growing
interest in the pathophysiological roles of XOR in a wide range
of disease processes [18–24]. For example, upregulation of XOR
activity has been implicated in various ischemic diseases and
leads to hyperuricemia, among other manifestations of reperfused
tissue injury [25]. Genetic deficiency of xor in mice has been
linked to renal fibrosis and disease [26,27].
In this investigation, we sought to inventory the metabolic
consequences that occur in plasma metabolite levels in mice with a
functional deficiency in XOR and evaluate the capability of an
untargeted LC-MS-based platform for profiling both predicted
and unforeseen changes. Although the direct enzymatic role of
XOR in mammalian purine degradation is established from
studies of the isolated enzyme [28–32], the inferred purine-
independent actions of XOR [26–29,33,34] and secondary
downstream metabolic perturbations that can arise from purine-
dependent and -independent actions remain to be defined.
In this post-reductionist era of protein science, there is a
growing appreciation for the idea that protein functions should be
studied and understood in the context of native physiological
microenvironments [35]. Since plasma provides the predominant
reservoir of metabolites for cellular ingress and egress, and
metabolites are the final downstream effectors of genes, the
plasma metabolome can be used to globally inform on the
organismal consequences of altered gene expression and drug
treatments. Thus, global plasma metabolite profiling offers the
potential to provide a broad overview of effects that may be
induced by drug actions and altered gene expression, rendering
plasma metabolite profiling as a promising technology for in vivo
functional genomics/proteomics. We demonstrate in this report
that untargeted plasma metabolite profiling, using LC-MS with
advanced chemometric data mining, reveals predicted alterations
in purine degradation, but also identifies unanticipated functions
of XOR and discovers plasma biomarkers that inform on
emergent kidney failure.
Results
Technical Assessment of Plasma Metabolite Profiling
Performance
Plasma, the reservoir of circulating metabolites, can provide a
systems level read-out of the physiological state of an organism. To
determine the technical reproducibility of untargeted analyses of
plasma, we performed 56 repeat analyses on a 0.2 ml injected
volume of a single human plasma (5 ml total injection volume,
from a 25-fold diluted plasma sample) and analyzed the
consistency of findings. Using data acquired by ANP chromatog-
raphy with positive ion detection, an overlay of total ion
chromatograms from the 56 repeat analyses revealed ,10%
run-to-run deviation (Fig. 1A). From these analyses, we tracked
variations in the detection levels of 374 distinct metabolites that
span the mass and chromatographic space of the dataset and
additionally differ in ion abundance over 3-orders of magnitude
(Fig. 1B). Considering the 56 repeated measurements of all 374
metabolites, normalized ion counts showed a mean coefficient of
variation (CV) of 6.51%, median CV of 5.91% and high/low CV
of 0.72% and 15.01%, respectively, considering all features. In
accord with this relatively low overall CV for metabolite
quantification, Fig. 1C shows extracted ion chromatography
depicting the reproducibility in quantifying some typical plasma
metabolites overlaying the 56 repeat measurements of cognate
peaks. The high technical reproducibility of plasma metabolite
quantification using this platform would predictably allow for
confident identification of biologically-relevant changes that are
$20% of control levels.
Metabolic Pathway Perturbation Elicited by xor Gene
Deletion
Employing a multimode analytical platform for expanded
feature coverage relative to that shown in Fig. 1, we analyzed
plasma from xor WT and xor KO mice in both positive (POS)
and negative (NEG) ionization MS detection modes, using both
hydrophilic (ANP, aqueous normal phase) and hydrophobic (RP,
reversed-phase) chromatographic separations. As shown in Fig. 2,
each of the four data acquisition modes contributed substantially
to feature coverage and only modest overlap was observed
between detection modes. Among the four detection modes,
ANP-POS LC/MS provided quantification of the greatest
number of features (2,004), followed by RP-NEG (1,123), RP/
POS (611) and ANP-NEG (406). Combining data from the 4
detection modes, a total of 3,716 unique features were quantified
with 100% frequency in either xor WT, KO, or both. Table 1
lists the verified identities of 52 metabolites found to be
differentially-expressed in KO vs. WT plasma, with p,0.05
and fold-change .2.0. As indicated in Table 1, xor gene
deletion was associated with a significant accumulation of some
plasma features (denoted by a positive Log2 value) and a
decrement in others (denoted by a negative Log2 value). In
accord with expectations, untargeted plasma metabolite profiling
revealed that xor gene deletion is associated with marked
increases in circulating levels of xanthine, hypoxanthine,
xanthosine and inosine, (XOR substrates and upstream metab-
olites in the purine salvage pathway), and depletion of uric acid
and allantoin (the XOR product and downstream metabolite).
Unexpectedly, xor gene deletion was also consistently associated
with various other metabolic pathways, seemingly unrelated to
purine metabolism; these include intermediates in metabolic
pathways for pyrimidines, the tricarboxylic acid (Krebs) cycle,
urea cycle, tryptophan, nicotinamide and phospholipids. Addi-
tionally, a series of small molecule biomarkers of kidney
dysfunction [36] were observed to accumulate in plasma from
xor KO mice, including creatinine, phenol, phenylsulfate,
indoxyl, indoxyl sulfate, quinol, quinol sulfate, N-methyl-4-
pyridone-5-carboxamide, N-Methyl-4-pyridone-2-carboxamide
and hippuric acid. The observed array of predicted metabolite
changes upstream and downstream of XOR enzyme activity
affirmed the potential of metabolite profiling as a systems biology
approach to identify gene functions, whereas unanticipated
findings suggested the possibility of unappreciated XOR activities
and unrecognized interactions of the perturbed purine salvage
pathway with other metabolic pathways.
Genotype-specific Metabolite Profiles Across Multi-
treatment Groups
Further studies were performed to assess the impact of xor gene
dosage on the plasma metabolome. Toward this end, we
compared plasma metabolite profiles from xor WT and KO mice
with plasma from xor heterozygous mice (HET). Further, we
sought to determine the extent to which the observed effects of xor
XOR Inactivation on the Murine Plasma Metabolome
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WT mice after pharmacological inhibition of XOR activity, using
the clinically-used drug, allopurinol (allopurinol treated group
designated as WTA). Considering only ANP-POS metabolite
profiling data in this expanded investigation, we observed a total of
8,360 unique aligned features in 18 plasma samples included in the
study. Of the 8,360 observed features, 1,240 were quantified with
100% frequency in at least one group. Fig. 3 depicts the changing
patterns of expression of these 1,240 reproducibly identified
plasma features across groups, comparing measurements from
WT, HET, KO and WTA mice. These profiles are plotted in
Fig. 3 as the average abundance in each group. Results indicate
striking similarities in the metabolite profile patterns of XOR-
inactivated mice (whether allopurinol-treated or xor-null) and
distinct differences from XOR-expressing mice (whether WT or
HET). Among the 1,240 metabolites, relative levels of xanthine,
hypoxanthine, uric acid and allantoin displayed pattern changes
predicted for XOR protein expression patterns in xor WT, HET,
KO and WTA. Numerous additional metabolites were observed
to follow identical plasma expression patterns as that of xanthine,
hypoxanthine, uric acid and allantoin, suggesting unappreciated
metabolic linkages.
Because untargeted metabolomic studies are exploratory in
nature and often result in large data sets, data analysis can benefit
markedly from interpretation using multiple statistical and
visualization tools. The goal of unsupervised pattern recognition
is to identify and display natural groupings in the data without
imposing any preconception about class membership. The PCA
score plot, shown in Fig. 4A, provides a three-dimensional
visualization of similarities and differences for all 1,240 plasma
metabolites recognized in 100% of samples from at least one
murine group. Each principal component (PC) represents the
weighted linear combination of original LC/MS data, shown in
the loadings plot (Fig. 4B), If two groups are found to differ in
metabolite expression along the PC1 axis, then the loadings plot
for PC1 can be used to determine which features contribute to the
greatest extent in producing this difference. PCA findings show
that xor WT and KO groups are clearly distinguished, reflecting
distinct xor genotype-based differences in the respective plasma
metabolomes. The xor HETs exhibited mixed pattern changes in
their metabolite profiles, with 3/6 more closely resembling WT
Figure 1. Technical reproducibility of plasma metabolite profiling. (A) Overlay of chromatograms acquired for 56 repeated analyses of a
single plasma sample, assessing the consistency of ion count measurements. (B) Profile plot overlay of normalized extracted ion intensities for 374
distinct metabolites, quantified as a function of injection number for the 56 repeated plasma analyses depicted in A. Results depict flat run-to-run
variation (mean CV=6.51%) in the levels of the 374 metabolites with repeated analysis. (C). Peak overlay of 56 repeated assessments of extracted ion
counts for detection of some typical plasma metabolites, demonstrating reproducibility of quantification.
doi:10.1371/journal.pone.0037149.g001
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KO are essentially inseparable along PC1, but clearly distin-
guished along PC2, reflecting a predominant component of XOR
phenotype (activity) similarity in this parameter, despite genotype
dissimilarity. This suggests that the genetic background of WTA
may be inferred from PC2, while the influence of XOR inactivity
may be revealed by PC1. Indeed, the dual contribution of XOR
activity (PC1) and xor genotype (PC2) may be explicitly projected
and visualized by the PCA score plot. It can also be seen in Fig. 4A
that there is a clear trajectory from WT to HET, then KO,
consistent with progressive changes in metabolism with increasing
degrees of xor gene inactivation. The extent to which individual
metabolites contribute to the changes along PC1 and PC2 can be
evaluated by consideration of the loadings plot, depicted in
Fig. 4B. Importantly, uric acid, xanthine, xanthosine, hypoxan-
thine, methylnicotinamide were found to be among the top
loading metabolites for PC1, while glycerophosphotidylcholine,
ceramides, myoinositol and several metabolites with undefined
molecular structures were found to have the largest impact on PC2
(i.e., contribute most profoundly to observed metabolic differences
in xor KO vs. WT mouse plasma).
Consistent with unsupervised pattern recognition found by
PCA, the HCA dendrogram also showed reproducible patterns of
within-group similarity and between-group differences in the
1,240 plasma features that could be quantified in all members of at
least one group (Fig. 4C). Notably, groups sharing the phenotype
of XOR inactivity (i.e. xor KO and WTA mice) exhibited
significant and substantial correlation in their patterns of
metabolite expression, clearly distinguishing these groups from
mice that express active XOR (i.e. xor HET and WT mice).
Welch ANOVA with Tukey’s HSD (Honestly Significant
Difference) for post hoc testing revealed a total of 541 statistically
different features in a group-by-group comparison of KO, WTA,
WT and HET mice (Fig. 5A). KO and WTA showed the greatest
number of feature differences from WT. Of 220 and 186
statistically-significant feature differences in KO vs. WT and
WTA vs. WT, respectively, 134 were changed in common
(Fig. 4B). These 134 conserved plasma metabolite feature changes
that arise in association with suppressed XOR activity –
irrespective of whether XOR is suppressed by gene deletion or
pharmacological inhibition - suggests that these metabolic
perturbations specifically arise from XOR enzyme inactivity.
Fig. 5C shows the identity of metabolites found to be consistently
upregulated or downredulated in both KO and WTA mouse
plasmas, relative to WT. Apart from the anticipated changes in
purine metabolites (i.e. xanthine, hypoxanthine and uric acid), we
observed metabolites that are methylated or involved in methyl
group transfer to be consistently upregulated in KO and WTA
mouse plasma (i.e., S-adenosylmethionine, N-methylnicotinamide,
and 1-methylhistidine). Additionally, KO and WTA mice
exhibited a series of differentially expressed metabolites showing
opposite changes, compared to WT, suggesting that these
differences do not arise as a simple consequence of XOR enzyme
inactivity (Fig. S1). These discordant features included glycer-
ophosphocholines, ceramides and some of the urea cycle and
polyamine pathway metabolites, which were significantly elevated
in plasma from xor KO mouse plasma, but unchanged after
allopurinol treatment (relative to WT).
Physiological Correlations
Untargeted plasma metabolite profiling revealed biomarkers
consistent with kidney failure. To investigate the veracity of this
possibility, we compared renal function and histology in xor KO
mice vs. xor HET and WT mice. Using standard assays for renal
function, xor KO mice exhibited conspicuous kidney failure at 14
days of life, when plasma was acquired for metabolite profiling.
Kidney failure was evidenced by a marked elevation of plasma
Figure 2. Broad murine plasma feature detection acquired by summed findings acquired using four different LC/MS detection
modes. Chromatographic modes comprised aqueous normal phase (ANP) for hydrophilic molecules and reverse phase chromatography (RP) for
hydrophobic molecules, with MS detection of both positive (POS) and negative (NEG) ions. As shown, all modes contributed substantially to feature
coverage and only modest overlap was observed between detection modes. Notably, among the four detection modes, ANP-POS LC/MS allowed for
quantification of the greatest number of features (2,004), followed by RP-NEG (1,123), RP/POS (611) and ANP-NEG (406). Combining data from all 4
acquisition modes, a total of , 3,716 unique features were detected with 100% frequency in plasma from xor WT, KO, or both mouse groups.
doi:10.1371/journal.pone.0037149.g002
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Metabolite/Pathway
Molecular
Formula
Mass
(measured)
Mass
deviation
(ppm)
RT
(min)
Fold-change
(Log2)* p-value
Major
detection
mode
Purine pathway
Xanthine C5H4N4O2 152.0337 22.7 1.621 16 6.1e25 ANPPOS
Xanthosine C10H12N4O6 284.0771 24.8 1.759 16 6.1e25 ANPPOS
Hypoxanthine C5H4N4O 136.0389 23.1 2.022 8.08 0.010 ANPPOS
Adenosine C10H13N5O4 267.0971 0.0 2.476 3.09 0.021 ANPPOS
Inosine C10H12N4O5 268.0813 20.8 1.756 16 0.025 RPNEG
Uric acid C5H4N4O3 168.0287 22.3 1.678 216 6.2e24 ANPPOS
Allantoin C4H6N4O3 158.0437 20.1 1.574 216 3.2e24 ANPPOS
Pyrimidine pathway
Uridine C9H12N2O6 244.0694 20.2 1.103 16 2.0e25 RPNEG
Dihydrouridine C9H14N2O6 246.0846 22.6 1.695 2.27 0.0011 ANPPOS
Dihydrouracil C4H6N2O2 114.0433 3.9 1.533 2.13 0.0042 ANPPOS
Citric acid cycle
Malate C4H6O5 134.0215 2.7 1.018 16 5.7e24 RP-NEG
Aconitate C6H6O6 174.0170 3.5 1.191 3.69 3.0e24 RP-NEG
Fumarate C4H4O4 116.0110 20.5 1.050 3.72 0.022 RPNEG
Citrate C6H8O7 192.0270 0.2 1.155 2.31 0.0050 RP-NEG
Ketoglutarate C5H6O5 145.038 23.5 1.057 5.64 8.2e24 RP-NEG
Pyruvate C3H4O3 88.0160 21.2 1.144 1.94 0.0058 RP-NEG
Tryptophan pathway
Kynurenic acid C10H7NO3 189.0426 21.3 1.695 3.82 0.0039 ANPPOS
Xanthurenic acid C10H7NO4 205.0374 20.1 3.288 3.35 0.042 ANPPOS
Indoxyl C8H7NO 133.0529 21.4 3.534 2.37 0.0086 RP-NEG
Indoxylsulfate C8H7NO4S 213.0096 21.7 3.536 2.19 0.0078 RPNEG
Tryptophan C11H12N2O2 204.0892 2.2 4.420 22.27 0.041 ANPPOS
Urea cycle and related
Argininosuccinate C10H18N4O6 290.1250 0.7 11.363 16 4.2e25 ANPPOS
Fumarate C4H4O4 116.0110 21.5 0.755 3.72 0.022 RPNEG
Proline C5H9NO2 115.0636 23.7 6.996 1.29 3.4e24 ANPPOS
Ornithine C5H12N2O2 132.0899 20.3 12.534 1.25 2.7e24 ANPPOS
N-Acetylornithine C7H14N2O3 174.0994 23.1 8.599 1.59 0.045 ANPPOS
Citrulline C6H13N3O3 175.0961 22.3 8.601 1.22 0.031 ANPPOS
Homocitrulline C7H15N3O3 189.1124 23.9 8.576 1.72 5.7e25 ANPPOS
Urea CH4N2O 60.0329 28.0 1.873 1.74 3.8e25 ANPPOS
Nicotinamide pathway
N-Methylnicotinamide C7H8N2O 136.0635 0.0 11.295 2.24 0.033 ANPPOS
N-Methyl-2-pyridone-5-carboxamide C7H8N2O2 152.0583 0.2 2.450 1.74 6.2e25 ANPPOS
N-Methyl-4-pyridone-5-carboxamide C7H8N2O2 152.0583 4.7 1.867 2.2 1.8e24 ANPPOS
Niacinamide C6H6N2O 122.0483 22.7 1.846 21.55 2.2e25 ANPPOS
Phospholipid metabolism
Pantothenic Acid C9H17NO5 219.1111 21.8 1.357 2.63 1.6e24 ANPPOS
Myristoyl-lysophosphatidylcholine C22H46NO7P 467.3011 0.5 7.696 2.21 2.0e24 ANPPOS
Dioleoyl-phosphatidylethanolamine C41H78NO8P 743.5447 2.4 1.748 2.14 1.0e24 ANPPOS
Dioleoyl-phosphatidylcholine C44H84NO8P 785.5937 20.4 4.560 1.65 0.021 ANPPOS
Glycerolphosphocholine C8H20NO6P 257.1035 2.8 12.172 21.88 0.0080 ANPOS
Renal disease markers
Creatinine C4H7N3O 113.0590 2.5 6.776 16 1.0e27 ANPPOS
Quinol C6H6O2 110.0362 0.6 2.416 3.78 0.0039 RPNEG
XOR Inactivation on the Murine Plasma Metabolome
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(Fig. 6A) concomitant with severe hypouricemia (Fig. 6B).
Additionally, kidney size was markedly diminished at 14 days,
compared to xor WT and HET littermates (Fig. 6C). The build-
up in plasma xanthine and hypoxanthine that we observed by
untargeted metabolite profiling in xor KO mice was associated
with the deposition of birefringent crystalloid concretions in the
renal tubules, focally present as sludge in the renal pelvis
(Fig. 6D–F). These crystalloids were occasionally observed to
penetrate tubular epithelial cells, but were mostly intraluminal
and partially-to-completely obliterative (i.e., resulting in variable
degree of tubular dilation, predominantly affecting the outer
cortex or the papillary tips). There was also a variable degree of
papillary attenuation, suggestive of obstructive uropathy. In
contrast, wildtype mice showed no significant kidney pathology
and heterozygote mice exhibited mild focal simplification of
glomerular capillary tufts with much more modest cortical
tubulointerstitial scarring. Taken together, these analyses verified
aberrant kidney structure and function in xor gene-deleted mice,
in accord with predictions based on observed metabolic
biomarkers of kidney dysfunction inferred from untargeted
plasma profiling analysis.
Discussion
XOR is not only the terminal enzyme in purine metabolism,
catalyzing the oxidation of purine metabolites to uric acid, but it
has also been implicated as a determinant of adipogenesis and
peroxisome proliferator-activated receptor-c activity [33], cyclo-
oxygenase-2 gene expression [26], catalytic conversion of nitrate
and nitrite to nitric oxide [29,34], catalytic hydroxylation of a wide
range of N-heterocyclic and aldehyde substrates [29], and may
also provide an endogenous source of ROS formation for cell
signaling [37,38]. XOR activity is subject to both pre-transcrip-
tional and post-transcriptional control by mechanisms that are
modulated by hormones, cytokines and oxygen tension [29].
Given the multifunctional and poorly-defined systemic roles of
XOR, we employed global plasma metabolite profiling in attempt
to define XOR functions in mice and additionally, to assess the
efficacy of untargeted profiling as an effective discovery approach.
Taken together, our findings revealed unexpectedly broad XOR
Table 1. Cont.
Metabolite/Pathway
Molecular
Formula
Mass
(measured)
Mass
deviation
(ppm)
RT
(min)
Fold-change
(Log2)* p-value
Major
detection
mode
Quinol sulfate C6H6O5S 189.9929 1.0 2.417 2.49 0.0059 RPNEG
Hydroxyhydroquinone C6H6O3 126.0314 2.7 1.670 1.08 0.0021 ANPPOS
Phenol C6H6O 94.0420 23.6 2.902 2.64 0.039 RPNEG
Phenylsulfate C6H6O4S 173.9985 21.4 2.901 2.29 0.046 RPNEG
Hippuric acid C9N9NO3 179.0609 21.9 1.131 2.55 0.0066 ANPNEG
2-hydroxyphenylacetate C8H8O3 152.0472 0.1 7.986 1.21 0.048 RPNEG
Other metabolites
Proline betaine C7H13NO2 143.0948 21.4 9.834 1.65 8.0e24 ANPPOS
Myo-inositol C6H12O6 180.0634 23.8 3.345 1.84 4.8e25 ANPPOS
3-Aminobenzoic acid C7H7NO2 137.0481 23.1 9.058 2.39 4.3e24 ANPPOS
Hydroxyadipic acid
{ C6H10O5 162.0530 21.3 2.211 21.36 0.0091 ANPPOS
1-Methylhistidine C7H11N3O2 169.0854 21.8 12.673 2.92 0.022 ANPPOS
S-Adenosylmethionine C15H23N6O5S 399.1427 23.5 13.01 22.07 0.0019 ANPPOS
*Positive values indicate increased plasma levels in xor KO vs. WT, whereas negative values denote a decreased plasma levels in xor KO vs. WT.
{Identified as mixtures of 2–hydroxyadipic acid and 3-hydroxyadipic acid.
doi:10.1371/journal.pone.0037149.t001
Figure 3. Patterns of change in murine plasma metabolite
levels associated with XOR activity suppression. Striking
similarities in plasma metabolite profiles are depicted in mice with
deficient XOR activity (arising from either homozygous xor gene
deletion or from allopurinol treatment; KO and WTA, respectively) vs.
XOR-expressing mice (both xor HET and WT). Each line represents the
levels of one of 1240 metabolites (quantified in all members of at least
one group by ANP-POS), connected by its normalized abundance across
groups. Color hues represent a heat map of normalized abundances
(0.0–5.0), ranging from blue (cold) to red (hot).
doi:10.1371/journal.pone.0037149.g003
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ering primary, secondary, and tertiary biochemical derangements
that apparently arise from deficient XOR enzyme activity.
Further, plasma metabolome derrangements in xor-deleted mice
indicated end-stage kidney failure, which was confirmed by
histochemically-defined renal pathologies and marked hypercrea-
Figure 4. Separation of treatment groups by unsupervised principal component analysis (PCA) and hierarchical clustering analysis
(HCA). (A) PCA score plot showing a three dimensional visualization of similarities and differences between each of the samples. Each data point
corresponds to one sample with a 3-D (the first three principal components) projection of 1,240 metabolites. Clustering and separation of all samples
indicates a gene dose trajectory in metabolite profile across groups. KO and WTA separated from WT along both PC1 (X-axis), which accounts for
39.4% of total variance. (B) PCA-loading plot showing 1,240 weighed metabolites contributing to the separation along PC1 and PC2 seen in score plot
in panel A. Metabolites are colored by mass and shaped by compound. Identified metabolites contributing most strongly to the separation are
indicated. Xanthine, hypoxanthine, xanthosine and urea were identified as up-regulated metabolites contributing dominantly to the separation along
PC1, while uric acid and allantoin are among the down-regulated features that contribute most significantly to the separation along PC1. (C)
Unsupervised HCA, based on the Pearson correlation, shows clustered within-group expression patterns for 1,240 quantified plasma features and
significant differences in between-group expression. Feature intensity is depicted as a heat map, ranging from cold (blue) to hot (red) and was
visualized using GeneSpring MS 1.2 software. Notably, mouse groups co-cluster with no-or-low XOR activity (xor KO and allopurinol-treated xor WT)
and are clearly distinguished from mice with relatively higher XOR activity (xor HET and WT).
doi:10.1371/journal.pone.0037149.g004
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with interstitial fibrosis in the kidney and renal tubular accretions
containing xanthine/hypoxanthine crystalloid matter (Fig. 6),
consistent with a prior report [27].
A schematic model is presented in Fig. 7 that seeks to link
primary, secondary and tertiary metabolic events that arise from
xor gene deletion, as molecular underpinnings for renal patho-
physiological consequences. In addition, a curated metabolic
metabolic network that quantifies XOR gene-deletion induced
changes is shown in supplemental Fig. S2. Primary metabolites
that are upstream and downstream to XOR in the purine salvage
pathway (i.e., xanthine, hypoxanthine and uric acid) were
consistently identified in our study by untargeted profiling as
among the most influential features that distinguish the plasma
metabolome of both xor KO and allopurinol-treated mice from
WT mice. We posit that the accumulation of primary XOR
substrates (i.e., xanthine and hypoxanthine), drives an accelerated
flux through the purine salvage pathway, accounting for substan-
tial observed increases in secondary purine metabolite levels in
plasma (i.e., xanthosine, inosine, adenosine and derived species).
Accumulated xanthine and hypoxanthine provide abundant
substrates for purine nucleoside phosphorylase 1 (PNP1), a purine
salvage pathway enzyme that catalyzes the reversible phosphorol-
ysis of purine nucleosides and inorganic phosphate, yielding the
corresponding purine bases and ribose-1-phosphate. Notably, in
addition to its service in the purine salvage pathway, PNP1 also
catalyzes the inter-conversion of deoxyuridine to uracil (pyrimi-
dine pathway) and N-ribosyl-nicotinamide to nicotinamide (nico-
tinamide metabolism). Given this involvement of PNP1 in multiple
purine-independent pathways, elevated levels of secondary purine
metabolites would predictably compete for the occupancy of
PNP1, thereby interfering with the metabolism of other biomol-
ecules that similarly rely on PNP1– this includes aberrant levels of
pyrimidine and nicotinamide intermediates, considered in Fig. 7
Figure 5. Statistically significant XOR activity-dependent differences in mouse plasma metabolite expression across groups. (A)
Welch one-way ANOVA with Turkey Posthoc testing shows 541 statistically different metabolites in a group-by-group comparison (corrected,
P,0.05). Numbers in pink and red cells denote significant and very significant metabolites between two groups, respectively. Blue denotes the
number of metabolites showing no difference between two groups, and grey refers to the total number of differentially-expressed metabolites across
all groups. (B) Venn diagram of the 220 and 188 differentially-expressed metabolites in KO and WTA compared to WT. Notably, KO and WTA share 134
differentially-expressed metabolites in common, compared to WT. (C) Differentially expressed metabolites showing similar changes in KO and WTA
compared WT. Data points refer to metabolite ion abundance from 4 groups: WT (black circles), HET (blue triangles), KO (red squares) and WTA (green
diamonds). The abundance of undetectable level of metabolites were assigned to 10 and plotted as one overlaid symbol. Identical metabolite
abundance was plotted as one overlaid symbol. P-values comparing KO vs. WT and WTA vs. WT were calculated based on a 2-tailed Student’s t-test.
Fold-changes were calculated based on the ratio of means for each group.
doi:10.1371/journal.pone.0037149.g005
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Notably, as shown in Table 1, pyrimidine and nicotinamide
pathway metabolites were significantly perturbed in xor KO mice
and this finding extended to allopurinol-treated xor WT mice.
Competition for PNP1 by accumulated purine intermediates may
also explain a prior report demonstrating significantly altered
levels of uridine, uracil, cytosine, and nicotinamide in xor-deleted
Drosophila [39].
The molecular basis for renal failure in mice with suppressed
XOR activity is obscure, but is presumed to be triggered by
primary, secondary, or tertiary metabolic perturbations that result
from XOR deficiency, perhaps further enhanced in xor KO mice
by a defect in kidney development. Notably, beyond the clinical
gold standard biomarkers of kidney failure, creatinine and urea,
untargeted plasma metabolite profiling identified numerous
additional upregulated levels of biomarkers that are associated
with kidney failure – these include phenols, indoxyl and its phase-
II metabolite indoxylsulfate, quinol and its phase-II metabolites
quinol sulfate [40] and quinol glunuronide, hippuric acid,
hydroxyphenylacetate, trimethylamine-N-oxide. Polyamines,
found at elevated level in renal disease patients’ plasma [41],
were also significantly elevated in xor KO mice. Indoxyl sulfate is a
protein-bound uremic toxin that is mainly produced by gut
bacteria-mediated decomposition of dietary tryptophan in the
intestine and accumulates in the plasma of patients with chronic
kidney disease [40]. Serum indoxyl sulfate was shown to be
associated with mortality in chronic kidney disease patients [42].
Impaired clearance of uremic toxins by the kidney results in their
Figure 6. Comparison of renal function and histology in xor2/2, xor+/2 xor+/+ mice. Renal function was assessed based on day 21 levels of
plasma creatinine (A) and uric acid (B). Bars denote mean values +/2 SEM; n=3–4 mice. Asterisks denote p,0.05, compared to xor wild type. (D) H&E
stained full thickness kidney section of a typical kidney from a xor KO mouse. Pathologic findings varied from focal deposits in mildly dilated cortical
and papillary tubules to markedly attenuated renal parenchyma with large patchy scars, the latter most prominent in the areas with crystalloid
deposits shown in the panel inset (10x original magnification). Note intratubular neutrophils frequently surrounding the crystalloid deposits in the
tubular lumina mixed with necrotic debris (E) Panel D, viewed under polarized light, revealing the distribution of intratubular crystalloid deposits. (F)
H&E stained kidney sections, visualized under polarized light with a yellow filter, 100 6 original magnification. Brightly birefringent intratubular
crystoliths were frequently observed, penetrating the tubular epithelial cells with apparent damage.
doi:10.1371/journal.pone.0037149.g006
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oxidative stress. Accumulation of these uremic toxins in plasma of
xor KO mice may be either a cause or effect of renal kidney failure.
Less well explained metabolite changes associated with XOR
inactivation in our study included increases in the apparent
activity of the oxidative tryptophan/kynurenine pathway, TCA
cycle and urea cycle (Table 1). Prior literature suggests that these
metabolic perturbations could arise from kidney failure, possibly
triggered by primary, secondary or tertiary metabolic consequenc-
es of insufficient XOR activity. For example, it has been shown
that kynurenic acid, xanthurenic acid and kynurenine 3-hydrox-
ylase activity are significantly increased in chronic renal failure in
patients [43–45]. Moreover, the accumulation of L-kynurenine
and its degradation product was found to be proportional to the
severity of renal failure and correlated with the plasma concen-
tration of renal insufficiency biomarker, creatinine [43]. Similarly,
plasma levels of urea and the urea cycle intermediates ornithine
and citrulline are elevated in renal failure patients, while arginine
and aspartate have been shown to remain relatively constant [46].
We found that some urea cycle intermediates are also elevated in
xor KO mouse plasma (ornithine, citrulline and argininosuccinate),
along with some downstream metabolites (polyamines and
proline), while levels of arginine and aspartate did not change
(Table 1). Thus, kidney failure in xor KO mice may underlie our
observed plasma accumulation of tryptophan oxidation products
and urea cycle metabolites and related species. Finally, serum
levels of the TCA cycle intermediates citrate, fumarate, oxaloac-
etate and malate have been reported to be significantly increased
in human renal disease patients and appear to be correlated with
disease progression and severity [47]. Thus, the elevated level of
TCA cycle intermediates we observe in xor KO mice is in accord
with that seen in human renal disease patients and may also be a
consequence of kidney dysfunction, contributing to the failure of
xor KO mice to thrive.
Plasma phospholipids, especially phosphatidylcholines and
ceramides were observed to increase in xor KO mice, but not in
allopurinol treated WT mice (Fig. S1). Increased plasma
phosphatidylcholines in KO mice is in accord with a prior report
demonstrating an essential developmental role for xor gene
expression during adipogenesis in mouse embryos [33]. Enhanced
expression of adipogeneis-related genes was previously described
in xor-disrupted mice with the accumulation of glyceride-rich lipids
in the renal tubules [27]. In contrast, allopurinol treatment was not
found to inhibit adipogenesis or lipid-droplet formation in a
human XOR transfected pre-adipocyte cell line [33], raising the
possibility that the adipogenic activity of xor may be limited to a
discrete period during embryonic development. Alternatively, the
adipogenic activity of xor may be mediated by the XDH activity of
XOR, which is not inhibited by allopurinol. Notably, mammalian
XOR exists in two interconvertible forms, XO and XDH, with the
Figure 7. Schematic model for XOR insufficiency-induced primary, secondary and tertiary metabolic consequences, culminating in
kidney failure. The present study found metabolites in bold to be upregulated in xor KO mice and non-bold metabolites downregulated. This
model provides a framework that seeks to reconcile observed systemic consequences of xor gene KO on the murine plasma metabolome – see
Discussion for details.
doi:10.1371/journal.pone.0037149.g007
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active metabolite oxypurinol, inhibits the XO activity by binding
to the molybdenum site of the enzyme [48], but not the FAD site
of XDH which has a higher NADH oxidizing activity. Given that
XDH activity remains unperturbed with allopurinol treatment,
increased phospholipids in xor KO suggests the possible mediation
by the NADH oxidizing activity of XDH for adipogenesis and
PPAR-a ˜ activity.
The broad metabolic consequences we observed with high-dose
acute allopurinol treatment in mice warrants consideration for
allopurinol use in patients. Initially limited to the treatment of
patients with gout, allopurinol therapy has since been extended to
chronic stable angina [49], stroke [50], congestive heart failure
[51] and even chronic kidney disease [52]. Animal studies have
also demonstrated efficacy of allopurinol therapy in type II
diabetic mice [53] and in kidney diseases with a significant
tubulointerstitial component [54], among others. Escalating doses
of allopurinol have been advocated by some investigators, even in
the face of recognized renal insufficiency [49,55,56]. Although
allopurinol intolerance is usually mild, it occurs in 10–15% of
patients [57] and only in rare cases has more severe complications
been reported. Among those more severe complications are
Stevens-Johnson and hypersensitivity syndromes [57], DRESS
(drug reaction and eosinophilia syndrome) [58] and an increase in
the number of opportunistic infections in patients with inflamma-
tory bowel disease who receive allopurinol in combination with
thiopurine therapy [59]. Admittedly, severe adverse effects of
allopurinol in patients are rare; however subclinical renal
consequences may be more widespread. The data presented
herein provide a compendium of plasma biomarkers that may be
used to identify subclinical toxicity of allopurinol and also a
cautionary note for periodic monitoring of kidney function in
allopurinol-treated subjects.
In summary, the present study demonstrates the broad efficacy
of untargeted plasma metabolite profiling to render a systems
biology perspective on the consequences of XOR enzyme
inactivation, resulting from either gene deletion or pharmacolog-
ical inactivation. This comprehensive perspective goes well beyond
providing molecular identities of primary XOR substrates and
products, by additionally informing on the activity of pathways
that are linked to these molecules and the functional integration of
XOR with more distal metabolic pathways and physiological
systems. Untargeted metabolite profiling provides an unprece-
dented tool to illuminate the often obscure in vivo push-pull
connectivity of metabolic pathways and systemic consequences of
pathway perturbations.
Materials and Methods
Animals and Reagents
The animal study protocol was in accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals and approved by the New York Medical College
Institutional Animal Care and Use Committee. XOR+/2 mice
were obtained from Dr. Toren Finkel (NIH/NHLBI) or purchased
from an NIH breeding facility and bred locally. Homozygous
XOR knockout mice were obtained by screening progeny born to
heterozygous parents, followed by PCR amplification using
RedTaq ReadyMix PCR reaction mix (Sigma, Saint Louis,
MO) as described in Supplementary Information Legends (Text S1).
LC-MS grade acetonitrile (ACN) and ddH2O were purchased
from Fischer Scientific. OmniTrace glacial acetic acid and formic
were obtained from EMD Chemicals. All other chemicals and
standards were obtained from Sigma Aldrich in the best available
grade.
Sample Preparation for Metabolite Profiling
Plasma samples were diluted 1:25 with 70% ACN in ddH2O
containing 0.2% acetic acid. The diluted samples were briefly
vortexed and centrifuged for 5 min at 16,0006g to pellet
precipitated proteins. For aqueous normal phase (ANP) chroma-
tography [15], sample supernatants were directly transferred to
autosampler vials for analysis by HPLC-MS. For reversed phase
(RP) chromatographic separation, supernatants were dried down
under vacuum, then resuspended with 5% ACN in ddH2O
containing 0.1% formic acid before analysis by HPLC/MS.
LC-MS and LC-MS/MS Platforms for Metabolite Profiling
Untargeted metabolite profiling was performed using both ANP
and RP chromatographic separations (for resolution of polar and
nonpolar compounds, respectively), dual spray electrospray
ionization and high resolution accurate mass determination using
a time-of-flight (TOF) mass spectrometer. Notably, LC-MS
produces a continuous multidimensional data matrix, consisting
of retention time, mass to charge ratio, and ion abundance.
The LC system comprised a Cogent Diamond Hydride
TM
(ANP) column (2.16150 mm, 3.5 mm particle size; Microsolv
Technology Corp, Eatontown, NJ), a Zorbax SB-AQ (RP)
column (2.16100 mm, 1.8 mm particle size, Agilent Technolo-
gies, Santa Clara, CA), and a Model 1200 Rapid Resolution
LC system consisting of a binary pump, on-line degasser,
thermostated dual 54-well plate autosampler and a thermostated
column compartment (Agilent Technologies, Santa Clara, CA).
A precolumn replacement filter frit (0.5 mm, Upchurch Scien-
tific, Oak Harbor, WA) and rapid resolution cartridge (Eclipse
XDB-C8, Agilent technologies) were placed in front of the ANP
and RP columns, respectively, to prevent column clogging. The
LC flow was coupled to an Agilent model 6230 accurate mass
time-of-flight (TOF) mass spectrometer, equipped with dual
spray electrospray ionization (ESI) source. A separate isocratic
pump was used deliver an internal reference mass solution (ions
m/z 121.0509 and 922.0093) to the second ESI source for
continuous mass calibration during sample analysis. An Agilent
6538 UHD Accurate Mass Q-TOF with same ANP and RP
platform was used to conduct fragmentation analysis for
confident molecular identification. LC parameters were set as
follows for ANP separation: 5 ml injection volume, 0.4 ml/min
mobile phase flow rate, 25uC column temperature and 5uC
autosampler temperature. The mobile phase consisted of 0.2%
acetic acid in ddH2O (solvent A) and 0.2% acetic acid in ACN
(solvent B). Gradient steps were applied as follows: 0–2 min,
85% B; 2–3 min, to 80% B; 3–5 min, 80% B; 5–6 min, to 75%
B; 6–7 min, 75% B; 7–8 min, to 70% B; 8–9 min, 70% B; 9–
10 min, to 50% B; 10–11 min, 50% B, 11.0–11.1 min, 20% B;
11.1–14 min, 20% B; 14–14.1 min, 5% B; 14.1–24 min, 5% B;
24–24.1 min, 85% B and 24–34 min, 85% B. Both positive and
negative mass spectra were acquired in 2 GHz (extended
dynamic range) mode with 1.41 spectra/sec sampled over a
mass/charge range of 50–1000 Daltons. The TOF capillary
voltage was set at 4000 V for positive ions and 3500 V for
negative ions with the fragmentor set to 175 V. The nebulizer
pressure was 35 psi and the nitrogen drying gas was 250uC,
delivered at a flow rate of 12 l/min. Data was saved in centroid
mode using Agilent MassHunter Workstation Data acquisition
Software (revision B346). For RP separation, the mobile phase
consisted of 0.1% formic acid in H2O (solvent A) or ACN
(solvent B). The gradient was as follows: 0–2 min, 5% B; 2–
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Other LC and TOF parameters used for RP chromatography
were the same as for ANP. To minimize potential salt and
other contaminants in the ESI source, a time segment was set
for both ANP and RP positive and negative acquisitions that
directed the first 0.2 ml of column elute to waste.
Data Processing and Analysis
Raw data files were processed using Agilent MassHunter
Qualitative Analysis Software (version B346). Untargeted
molecular feature extraction (MFE) [16,60] generates features
(compounds) based on the elution profile of identical mass and
retention times, within a defined mass accuracy (,5 ppm).
These features are further grouped into one or more
‘‘compounds’’ based on their isotope pattern, the formation of
dimer, adduct ions (e.g. H
+,N a
+,K
+ for positive mode and H
2,
CH3COO
2, HCOO
2 and Cl
2 for negative ion mode) and
common neutral losses of H2O and NH3. Compounds/features
with absolute peak heights of 1000 or greater were selected and
stored as compound exchange format (CEF) files for feature
alignment, data processing and multivariate statistical analysis in
Mass Profiler Professional (Agilent Technology, MPP, version
B2.02). Each aligned mass was associated with its neutral mass,
ion intensity and retention time. The aligned data were filtered,
considering only features that were detected in all biological
replicates from at least one sample group. To complement the
untargeted MFE findings and reduce false-positive and false-
negative detection rates, we further conducted recursive analysis,
wherein a composite list of ions found by MFE were targeted
for re-extraction against raw data for all potential ion species
(isotopes, adducts, dimers and trimers). The recursive CEF files
were re-imported into MPP to provide a higher confidence
analysis. Notably, recursive analysis is effective for finding
missing features that would otherwise result in overlooking
actual resident metabolites by subsequent statistical analysis.
Statistical Analysis
MPP was used to provide a multivariate statistical platform for
comparative metabolite profiling. Principal component analysis
(PCA) and hierarchical cluster analysis (HCA) are two unsuper-
vised pattern recognition algorithms used to examine data sets for
expected and unexpected clusters, including the presence of
outliers without prior sample grouping information. Aligned
features detected in all biological replicates of at least one group
were directly applied for a 3-dimentional visualization of the data.
One-way analysis of variance (ANOVA) was applied to find
metabolites showing statistical differences across groups. The
Benjamini Horchberg correction was applied to adjust for false-
positive discovery, arising from multiple testing of p-values
(adjusted for predicted p,0.05).
Differentially-expressed Metabolite Identification
A critical step in metabolite profiling is identification of
unknown metabolites. Differential metabolites with fold changes
greater than 2, compared to WT, were initially searched against
an in-lab annotated METLIN Personal Metabolite Database
(Agilent Technologies), based on accurate monoisotopic neutral
masses (,5 ppm). A molecular formula generator (MFG)
algorithm in MPP was used to generate and score empirical
molecular formulae based on a weighted consideration of
monoisotopic mass accuracy, isotope abundance ratios, and
spacing between isotope peaks. Notably, MFG imposes addi-
tional constraints on the list of candidate molecular formulas
detected by a METLIN database search. A putative compound
ID was tentatively assigned when METLIN and MFG
concurred for a given candidate. Tentatively assigned com-
pounds were verified based on a match of LC retention time
and/or MS/MS fragmentation patterns to pure molecular
standards. Fragmentation pattern matches were performed for
the identification of positional isomers that were unresolved by
HPLC and for relatively high molecular weight compounds
(600–1,000 Da), where ‘‘hits’’ based on MFG alone can exceed
100 and thus preclude confident molecular identification if
considered alone.
Kidney Histology and Assays
Kidneys (from 3–5 mice for each xor genotype) were fixed in 4%
paraformaldehyde and embedded in paraffin. Sections (3–4
microns) were stained with hematoxylin/eosin (H&E), periodic
acid-Schiff reagents (PAS) and Masson’s trichrome for routine
histology. Xanthine and hypoxanthine crystals were visualized by
darkfield and polarized light microscopy.
Supporting Information
Figure S1 Box-whisker plot depicting metabolites that change
significantly in xor KO vs. WT mice (P,0.05), but not significantly
different in WTA (allopurinol-treated) vs. WT mice. The bottom
and top of the box denote the 25
th and 75
th percentile of the ion
intensity. The whiskers represent the maximum and minimum of
the data. The median and mean are represented as solid and
dashed lines, respectively, within each box.
(TIFF)
Figure S2 Curated network, depicting the global metabolic
consequences of XOR gene deletion. Pathways are plotted using
PathVisio (http://pathvisio.org/), a non-proprietary online access
tool for displaying and editing biological pathways. Metabolic
linkages are from KEGG pathway maps (http://www.genome.
jp/kegg-bin/
show_organism?menu_type=pathway_maps&org=mmu and
presented using the following nomenclature to denote biological
entities: gene products, black font in a black box; metabolites,
blue font in a blue box. The pathway is further annotated with
KEGG IDs of metabolites and the Entrez gene IDs of gene
products. Observed XOR-knockout associated changes in
metabolite expression are quantified as Log2 fold-change, relative
to XOR wildtype control, and denoted in green for molecules
with levels that are upregulated and red for molecules that are
downregulated. Metabolites without annotated fold-changes were
either undetected by LC-MS or exhibited no significant change
from control levels.
(TIFF)
Text S1 PCR screening of murine xor genotypes.
(DOCX)
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